Tales From The Road

More frequently than not LSN captures content through its RESI panels that hits the nail on the head. The recent “Tales from the Road” Panel does just that. It’s 50 minutes long but worth a viewing it if you are a scientist-entrepreneur or fundraising CEO. The most vital take-aways include how to source potential investors (particularly family offices), the process of “working” your pipeline of investors, and the costs associated with conducting a successful campaign.

The panel brought together successful biotech and medtech entrepreneurs to tell their stories of successfully raising capital. These are seasoned entrepreneurs who have been there done that and collectively have raised numerous private financing rounds and have exited multiple companies. They came to RESI Boston to share their wisdom to fellow fundraising executives and provide insight in order to help their peers succeed.


Donna LaVoie, President & CEO, LaVoieHealthScience

Donna is a proven strategic communications executive in biotechnology, healthcare, medical device and pharmaceutical fields. She is a trusted advisor on strategic communications issues. Started in 2001, LaVoieHealthScience is a strategic public relations agency providing corporate communications, public relations and investor relations to some of the world’s innovative companies in the sector. For the last fifteen years, Donna’s efforts combine building LaVoieHealthScience’s pharmaceutical and life science practices, strategic direction and core competencies. LaVoieHealthScience is an acknowledged leader in health science strategic communications and recognized as a top 30 independent healthcare agencies in the US. The agency has received 29 awards in the past 7 years for its client work.

Donna’s focus is in helping clients build their companies and brands during transformational times. Her approach centers on bringing a credible voice to key audiences while providing strategic counsel that builds value and stakeholder engagement.
Client representation consists of growth businesses in health and science in the US, Europe and Asia covering complex communications issues. She also serves as a connector of clients to industry, banking, investor and media contacts.


Rob Hedequist, President & COO, Kineta

Rob Hedequist serves as Kineta’s President and Chief Operating Officer. Mr. Hedequist previously held the roles of Chief Development Officer at KPI Therapeutics (a Kineta subsidiary) and Senior Vice President of Corporate Development at Kineta. Mr. Hedequist brings over 25 years of product launch and biopharmaceutical industry experience to Kineta. In his roles at Kineta he and his teams have been responsible for raising over $35M in capital. He has held numerous leadership roles within the commercial sales and marketing organizations of Fortune 100 pharmaceutical and biotechnology companies.

Prior to joining Kineta in 2013, he was responsible for managed care and Medicaid account management at Amgen. Before Amgen, he was a National Director for Schering-Plough and responsible for developing and implementing strategy across 16 national regions. Mr. Hedequist started his pharmaceutical career at Pfizer where he had increasing levels of responsibility culminating in Managed Market Manager where he coordinated product sales over $300 million per year. Over his career he has successfully launched over 10 new pharmaceutical products and 2 biological products. Prior to his career in the pharmaceutical industry, Mr. Hedequist had a stellar career in the United States Marine Corps rising from platoon commander to Major and Commanding Officer Fleet Anti-Terrorism Security Company Pacific and is a Desert Shield veteran. A former collegiate athlete, he was a member of the 1979 PAC10 Championship football team and graduated from the University of Southern California with a Bachelor of Science degree in Public Affairs.

 Joe Muldoon, CEO, FAST BioMedical

Mr. Joe Muldoon, CEO of FAST BioMedical, is a “serial entrepreneur”, who started his career as an E&Y trained CPA in their Entrepreneurial Services Department.

FAST BioMedical is a clinical stage medical technology company that has received a rare FDA Expedited Review.  The company’s globally patented technology is directed at uniquely serving a validated $10B unmet medical need market.

Mr. Muldoon leverages 30 years of business leadership, from running publicly traded multi-nationals, to guiding start-ups from inception, thru capitalization, commercialization and exit.  Joe is known for his intense focus on company culture and challenging traditional thinking to open up opportunity.    Under his leadership, FAST BioMedical has raised $30M, and taken initial discoveries from Indiana University School of Medicine, the 2nd largest Medical School in the U.S., thru Phase IIB clinical trials.

Joe and the company have taken a very unique path for product development.   They have aggressively leveraged federal funding and university partnerships for what Joe refers to as “extreme capital efficiency”.  Going against conventional wisdom, the Company has turned down traditional venture capital, choosing to pursue capital on an alternative path.   A frequent panelist and speaker for MBA programs, Joe has stated “Single Family Offices are the future financers of truly disruptive innovation.  They are motivated to change the world and are opportunistic instead of formulaic.”

Joyce Lonergan, CEO & Co-Founder, Mellitus

Joyce Lonergan has over 25 years of experience in industry, venture capital and Wall Street with emerging healthcare companies. Ms. Lonergan previously served as a Managing Partner at SR One. Prior to that, Ms. Lonergan co-founded and served as Managing Director of Caxton Healthcare Venture Management, LLC. She previously served as Vice President of Corporate Development and Corporate Communications and Investor Relations at Chiron Corporation. Earlier in her career, Ms. Lonergan was a Biotechnology Equity Research Analyst at Cowen and Company. She also had previous investment and business development roles at Vector Fund Management and Repligen Corporation. Ms. Lonergan began her career in research at Tufts Medical Center.

Ms. Lonergan holds a B.S. in biology from Emmanuel College and an MBA from the Simmons College Graduate School of Management

Gregory Stein, President & CEO, Curtana Pharmaceuticals

Dr. Stein currently serves as the President and CEO of Curtana Pharmaceuticals, a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas that focuses on the development of novel first-in-class, small molecule therapeutics targeting cancer stem cells for the treatment of glioblastoma (GBM) and other brain cancers. During his professional career of over 25 years, he has been a clinician, a hospital administrator, and a life sciences executive with experience in the areas of diagnostics, medical devices, pharmaceuticals and biotechnology.

Dr. Stein is formerly board certified in Emergency Medicine. He completed his residency at the University of Illinois Affiliated Hospitals in Chicago and is a graduate of the 3-year accelerated Independent Study Program at the Ohio State University School of Medicine. Dr. Stein received a B.A in Psychology from UC San Diego and an MBA from The Rady School of Management at UC San Diego.

Go Back to Agenda